AN2 rises after early-stage trial data for Chagas disease therapy
Source: SeekingAlpha
2026-06-04 08:21:35 ET
More on AN2 Therapeutics
- AN2 Therapeutics, Inc. (ANTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
- AN2 Therapeutics GAAP EPS of -$0.29 misses by $0.06
- Seeking Alpha’s Quant Rating on AN2 Therapeutics
- Historical earnings data for AN2 Therapeutics
- Financial information for AN2 Therapeutics
Read the full article on Seeking Alpha
For further details see:
AN2 rises after early-stage trial data for Chagas disease therapy
AN2 Therapeutics Inc.
NASDAQ: ANTX
ANTX Trading
-4.5% G/L:
$4.03 Last:
39,734 Volume:
$4.19 Open:
ANTX Latest News
June 04, 2026 07:00:00 am
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
May 11, 2026 04:01:00 pm
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
May 07, 2026 04:01:00 pm
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
ANTX Stock Data
$30,142,226
20,699,489
1.32%
34
N/A
Biotechnology & Life Sciences
Healthcare
US
Menlo Park
